Europe Virology Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Diagnostic Test, Viral Infection Controlling Techniques, Antiviral Therapeutics, and Interferons), Application (Skin and Soft Tissue Infections, Respiratory Tract Infections, GI Tract Infections, Sexually Transmitted Diseases, Urinary Tract Infection, and Others), and End User (Hospitals, Diagnostic Laboratories, Pharmaceutical and Biotechnological Companies, and Research and Academic Institutes)
Market Introduction
The Europe virology market includes the consolidated markets for France, Germany, United Kingdom, Spain, Italy, and Rest of Europe. Europe occupies a significant position in the virology market and is expected to record vigorous growth rate during the forecast period. The growth of the market is attributed by the products developments done by the companies in the country like Germany and UK, strong research, and development activities, and increasing funding for research on emerging diseases. Influenza is a fatal disease for older people with chronic diseases. The mortality and morbidity of influenza are high in Germany. As per the Max-Planck Institute, around 13,600 people die during every flu season, and many deaths are from the older population. In October 2020, to reduce the risk of simultaneous influenza and COVID-19 outbreaks, Germany ordered an additional 6 million doses of flu vaccine. Also, as per The Robert Koch Institute, in 2019, an increase in Hepatitis E and leptospirosis cases was observed due to increased awareness of these diseases by physicians and increased laboratory testing. Germany has been at the forefront of developing new technologies and therapeutics due to its well-developed infrastructure and high investment. The presence of eminent research institutes has led to the launch of innovative therapeutics. Increasing product launches is the major factor driving the growth of the Europe virology market.
Emerging virus epidemics occur unexpectedly and demand rapid action to stop the disease from spreading. The most recent outbreak of COVID-19 worldwide highlights the need developing diagnostics, vaccines, and antiviral drugs on an urgent basis. As COVID-19 belongs to the coronavirus family, much research into MERS and the development of vaccines against it enabled the rapid advancement of vaccines against COVID-19. Therefore, developing prototype vaccines against potential viruses could greatly accelerate the development of vaccines against any emerging pandemic. For instance, Before COVID-19, The Coalition for Epidemic Preparedness Innovations (CEPI) had developed a robust portfolio of MERS vaccine candidates and invested more than US$140 million to MERS vaccine development, which later laid the groundwork for rapid response to COVID-19 and enabled rapid COVID-19 vaccine development, including the Oxford vaccine. Also, CEPI established a collaboration with the University of Oxford in 2018 to develop a vaccine against MERS using their ChadOx vaccine platform. CEPI provided additional funding to the University of Oxford to adapt this platform technology to develop a vaccine against COVID-19. To scale the manufacture of their COVID-19 vaccine candidate, the University of Oxford subsequently partnered with AstraZeneca, who committed to producing the vaccine on a non-profit basis during the pandemic. Therefore, the pandemic preparedness has helped launch vaccines in a short period, further emphasizing the need for more investment in emerging virus’s research. Europe has been investing in the research of emerging viruses for a long time. The Centre has contributed expertise to recent Ebola outbreaks and is now working on COVID-19. In addition, Vaccine approvals have raised hopes of eventually overcoming the pandemic. However, recent outbreaks and the emergence of new strains of the virus affect the economic outcomes, and a post-pandemic will require governments and the private sector to make long-lasting commitments to global epidemic and pandemic preparedness.
Get more information on this report :
Market Overview and Dynamics
The virology market in Europe is expected to grow from US$ 1,208.26 million in 2021 to US$ 1,521.97 million by 2028; it is estimated to grow at a CAGR of 3.4% from 2021 to 2028. Plant-derived vaccines and biopharmaceuticals do not need costly fermentation and purification systems and other costs associated with cold storage, transportation, and sterile distribution when administered orally. In general, chloroplasts deliver high levels of vaccine antigen expression against bacterial, viral, and protozoan pathogens and biopharmaceuticals and the containment of transgenes by maternal inheritance. In the past eight years, the chloroplast system for therapeutic protein expression has been established. Also, the recent development of an efficient lettuce chloroplast system for oral delivery is a significant advancement. Moreover, at-home health diagnostics is gaining popularity among patients. As a response to the virology market, players are developing at-home test kits that help in easy and quick diagnosis and help in taking immediate medical treatment.
Key Market Segments
The Europe virology market is segmented on the bases of type, application, end user, and country. Based on type, the market is segmented into diagnostic test, viral infection controlling techniques, antiviral therapeutics, and interferons. The antiviral therapeutics segment dominated the market in 2020, and viral infection controlling techniques segment is expected to be the fastest growing during the forecast period. The diagnostic test segment is further categorized into DNA virus testing, RNA virus testing, others. Similarly, the viral infection controlling techniques is bifurcated into active prophylaxis, and passive prophylaxis. Likewise, the antiviral therapeutics segmented is categorized into virucidal agents, antiviral agents, immunomodulators, and interferons. On the basis of application, the virology market is segmented into skin and soft tissue infections, respiratory tract infections, GI tract infections, sexually transmitted diseases, urinary tract infections, and others. The respiratory tract infections segment dominated the market in 2020, and is expected to be the fastest growing during the forecast period. On the basis of end user, the virology market is segmented into hospitals, diagnostic laboratories, pharmaceutical and biotechnological companies, and research and academic institutes. The hospitals segment dominated the market in 2020, and diagnostic laboratories segment is expected to be the fastest growing during the forecast period.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the virology market in Europe are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Abbott; AbbVie Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline Plc; Illumina, Inc.; Johnson and Johnson Services, Inc.; QIAGEN; Siemens AG; and Thermo Fisher Scientific Inc. are among others.
Reasons to buy report
- To understand the Europe virology market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for Europe virology market
- Efficiently plan M&A and partnership deals in Europe virology market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Europe virology market
- Obtain market revenue forecast for market by various segments from 2021-2028 in Europe region.
Europe Virology Market Segmentation
Europe Virology Market -By Type
- Diagnostic Test
- DNA Virus Testing
- RNA Virus Testing
- Others
- Viral Infection Controlling Techniques
- Active Prophylaxis
- Passive Prophylaxis
- Antiviral Therapeutics
- Virucidal Agents
- Antiviral Agents
- Immunomodulators
- Interferons
Europe Virology Market -By Application
- Skin and Soft Tissue Infections
- Respiratory Tract Infections
- GI Tract Infections
- Sexually Transmitted Diseases
- Urinary Tract Infections
- Others
Europe Virology Market -By End User
- Hospitals
- Diagnostic Laboratories
- Pharmaceutical and Biotechnological Companies
- Research and Academic Institutes
Europe Virology Market -By Country
- U.K.
- Germany
- France
- Italy
- Spain
- Rest of Europe
Europe Virology Market -Company Profiles
- Abbott
- AbbVie Inc.
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- GlaxoSmithKline Plc
- Illumina, Inc.
- Johnson and Johnson Services, Inc.
- QIAGEN
- Siemens AG
- Thermo Fisher Scientific Inc.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Virology Market – By Type
1.3.2 Europe Virology Market – By Application
1.3.3 Europe Virology Market – By End User
1.3.4 Europe Virology Market– By Country
2. Europe Virology Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Virology Market– Market Landscape
4.1 Overview
4.2 Europe PEST Analysis
4.3 Experts Opinion
5. Europe Virology Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Viral Infectious Diseases
5.1.2 Increasing Product Launches
5.2 Market Restraints
5.2.1 Availability of Alternative Products and High Cost of Production of Products
5.3 Market Opportunities
5.3.1 Growth Potential in Several Economies
5.4 Future Trends
5.4.1 Continuous Demand for Cost-Effective Products
5.5 Impact Analysis
6. Virology Market– Europe Analysis
6.1 Europe Virology Market Revenue Forecast and Analysis
7. Europe Virology Market Analysis – By Type
7.1 Overview
7.2 Europe Virology Market Revenue Share, by Type (2021 and 2028)
7.3 Diagnostic Test
7.3.1 Overview
7.3.2 Diagnostic Test: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.1 Deoxyribonucleic Acid (DNA) Virus Testing
7.3.2.1.1 Overview
7.3.2.1.2 DNA Virus Testing: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.2 Ribonucleic Acid (RNA) Virus Testing
7.3.2.2.1 Overview
7.3.2.2.2 RNA Virus Testing: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.3 Others
7.3.2.3.1 Overview
7.3.2.3.2 Others: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Viral Infection Controlling Techniques
7.4.1 Overview
7.4.2 Viral Infection Controlling Techniques: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.1 Active Prophylaxis
7.4.2.1.1 Overview
7.4.2.1.2 Active Prophylaxis: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.2 Passive Prophylaxis
7.4.2.2.1 Overview
7.4.2.2.2 Passive Prophylaxis: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Antiviral Therapeutics
7.5.1 Overview
7.5.2 Antiviral Therapeutics: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.1 Virucidal Agents
7.5.2.1.1 Overview
7.5.2.1.2 Virucidal Agents: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.2 Antiviral Agents
7.5.2.2.1 Overview
7.5.2.2.2 Antiviral Agents: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.3 Immunomodulators
7.5.2.3.1 Overview
7.5.2.3.2 Immunomodulators: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Interferons
7.6.1 Overview
7.6.2 Interferons: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8. Europe Virology Market Analysis – By Application
8.1 Overview
8.2 Europe Virology Market, by Application 2021 & 2028 (%)
8.3 Skin and Soft Tissue Infections
8.3.1 Overview
8.3.2 Skin and Soft Tissue Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Respiratory Tract Infections
8.4.1 Overview
8.4.2 Respiratory Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8.5 GI Tract Infections
8.5.1 Overview
8.5.2 GI Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Sexually Transmitted Diseases
8.6.1 Overview
8.6.2 Sexually Transmitted Diseases: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8.7 Urinary Tract Infections
8.7.1 Overview
8.7.2 Urinary Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Virology Market – Revenue and Forecast to 2028 (US$ Million)
9. Europe Virology Market Analysis – By End User
9.1 Overview
9.2 Europe Virology Market Revenue Share, by End User (2021 and 2028)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: Virology Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Diagnostic Laboratories
9.4.1 Overview
9.4.2 Diagnostic Laboratories: Virology Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Pharmaceutical and Biotechnological Companies
9.5.1 Overview
9.5.2 Pharmaceutical and Biotechnological Companies: Virology Market – Revenue and Forecast to 2028 (US$ Million)
9.6 Research and Academic Institutes
9.6.1 Overview
9.6.2 Research and Academic Institutes: Virology Market – Revenue and Forecast to 2028 (US$ Million)
10. Europe Virology Market – Country Analysis
10.1.1 Europe Virology Market Revenue and Forecasts to 2028, By Country (%)
10.1.1.1 UK Virology Market Revenue and Forecasts to 2028 (US$ million)
10.1.1.1.1 UK Virology Market Revenue and Forecasts to 2028 (US$ million)
10.1.1.1.2 UK Virology Market Revenue and Forecasts to 2028, By Type (US$ million)
10.1.1.1.2.1 UK: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)
10.1.1.1.2.2 UK: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)
10.1.1.1.2.3 UK: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)
10.1.1.1.3 UK Virology Market Revenue and Forecasts to 2028, by Application (US$ million)
10.1.1.1.4 UK Virology Market Revenue and Forecasts to 2028, by End User (US$ million)
10.1.1.2 Germany Virology Market Revenue and Forecasts to 2028 (US$ million)
10.1.1.2.1 Germany Virology Market Revenue and Forecasts to 2028 (US$ million)
10.1.1.2.2 Germany Virology Market Revenue and Forecasts to 2028, By Type (US$ million)
10.1.1.2.2.1 Germany: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)
10.1.1.2.2.2 Germany: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)
10.1.1.2.2.3 Germany: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)
10.1.1.2.3 Germany Virology Market Revenue and Forecasts to 2028, by Application (US$ million)
10.1.1.2.4 Germany Virology Market Revenue and Forecasts to 2028, by End User (US$ million)
10.1.1.3 France Virology Market Revenue and Forecasts to 2028 (US$ million)
10.1.1.3.1 France Virology Market Revenue and Forecasts to 2028 (US$ million)
10.1.1.3.2 France Virology Market Revenue and Forecasts to 2028, By Type (US$ million)
10.1.1.3.2.1 France: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)
10.1.1.3.2.2 France: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)
10.1.1.3.2.3 France: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)
10.1.1.3.3 France Virology Market Revenue and Forecasts to 2028, by Application (US$ million)
10.1.1.3.4 France Virology Market Revenue and Forecasts to 2028, by End User (US$ million)
10.1.1.4 Italy Virology Market Revenue and Forecasts to 2028 (US$ million)
10.1.1.4.1 Italy Virology Market Revenue and Forecasts to 2028 (US$ million)
10.1.1.4.2 Italy Virology Market Revenue and Forecasts to 2028, By Type (US$ million)
10.1.1.4.2.1 Italy: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)
10.1.1.4.2.2 Italy: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)
10.1.1.4.2.3 Italy: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)
10.1.1.4.3 Italy Virology Market Revenue and Forecasts to 2028, by Application (US$ million)
10.1.1.4.4 Italy Virology Market Revenue and Forecasts to 2028, by End User (US$ million)
10.1.1.5 Spain Virology Market Revenue and Forecasts to 2028 (US$ million)
10.1.1.5.1 Spain Virology Market Revenue and Forecasts to 2028 (US$ million)
10.1.1.5.2 Spain Virology Market Revenue and Forecasts to 2028, By Type (US$ million)
10.1.1.5.2.1 Spain: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)
10.1.1.5.2.2 Spain: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)
10.1.1.5.2.3 Spain: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)
10.1.1.5.3 Spain Virology Market Revenue and Forecasts to 2028, by Application (US$ million)
10.1.1.5.4 Spain Virology Market Revenue and Forecasts to 2028, by End User (US$ million)
10.1.1.6 Rest of Europe Virology Market Revenue and Forecasts to 2028 (US$ million)
10.1.1.6.1 Rest of Europe Virology Market Revenue and Forecasts to 2028 (US$ million)
10.1.1.6.2 Rest of Europe Virology Market Revenue and Forecasts to 2028, By Type (US$ million)
10.1.1.6.2.1 Rest of Europe: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)
10.1.1.6.2.2 Rest of Europe: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)
10.1.1.6.2.3 Rest of Europe: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)
10.1.1.6.3 Rest of Europe Virology Market Revenue and Forecasts to 2028, by Application (US$ million)
10.1.1.6.4 Rest of Europe Virology Market Revenue and Forecasts to 2028, by End User (US$ million)
11. Impact of COVID-19 Pandemic on Europe Virology Market
11.1 Overview
12. Europe Virology Market–Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview
13. Company Profiles
13.1 Abbott
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Johnson and Johnson Services, Inc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 F. HOFFMANN-LA ROCHE LTD.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 THERMO FISHER SCIENTIFIC INC.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 QIAGEN
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Illumina, Inc.
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Siemens AG
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 GlaxoSmithKline Plc
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 AbbVie Inc.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Gilead Sciences, Inc.
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Europe Virology Market Revenue and Forecast to 2028 (US$ Million)
Table 2. UK Virology Market Revenue and Forecasts to 2028, By Type US$ million)
Table 3. UK Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)
Table 4. UK Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)
Table 5. UK Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)
Table 6. UK Virology Market Revenue and Forecasts to 2028, by Application US$ million)
Table 7. UK Virology Market Revenue and Forecasts to 2028, by End User US$ million)
Table 8. Germany Virology Market Revenue and Forecasts to 2028, By Type (US$ million)
Table 9. Germany Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)
Table 10. Germany Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)
Table 11. Germany Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)
Table 12. Germany Virology Market Revenue and Forecasts to 2028, by Application US$ million)
Table 13. Germany Virology Market Revenue and Forecasts to 2028, by End User US$ million)
Table 14. France Virology Market Revenue and Forecasts to 2028, By Type (US$ million)
Table 15. France Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)
Table 16. France Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)
Table 17. France Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)
Table 18. France Virology Market Revenue and Forecasts to 2028, by Application (US$ million)
Table 19. France Virology Market Revenue and Forecasts to 2028, by End User (US$ million)
Table 20. Italy Virology Market Revenue and Forecasts to 2028, By Type (US$ million)
Table 21. Italy Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)
Table 22. Italy Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)
Table 23. Italy Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)
Table 24. Italy Virology Market Revenue and Forecasts to 2028, by Application (US$ million)
Table 25. Italy Virology Market Revenue and Forecasts to 2028, by End User (US$ million)
Table 26. Spain Virology Market Revenue and Forecasts to 2028, By Type (US$ million)
Table 27. Spain Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)
Table 28. North America Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)
Table 29. Spain Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)
Table 30. Spain Virology Market, by Application – Revenue and Forecast to 2028 by Application (USD Million)
Table 31. Spain Virology Market, by End User – Revenue and Forecast to 2028 by End User (USD Million)
Table 32. Rest of Europe Virology Market Revenue and Forecasts to 2028, By Type (US$ million)
Table 33. Rest of Europe Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)
Table 34. Rest of Europe Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)
Table 35. Rest of Europe Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)
Table 36. Rest of Europe Virology Market Revenue and Forecasts to 2028, by Application (US$ million)
Table 37. Rest of Europe Virology Market Revenue and Forecasts to 2028, by End User (US$ million)
Table 38. Organic Developments Done by Companies
Table 39. Inorganic Developments Done by Companies
Table 40. Glossary of Terms, Europe Virology Market
LIST OF FIGURES
Figure 1. Europe Virology Market Segmentation
Figure 2. Europe Virology Segmentation, By Country
Figure 3. Europe Virology Market Overview
Figure 4. Antiviral Therapeutics Held the Largest Share of the Type Segment in Europe Virology Market
Figure 5. Respiratory Tract Infections Held the Largest Share of the Application Segment in Europe Virology Market
Figure 6. UK to Show Significant Growth During Forecast Period
Figure 7. Europe and PEST Analysis
Figure 8. Europe Virology Market: Impact Analysis of Drivers and Restraints
Figure 9. Europe Virology Market– Revenue Forecast and Analysis – 2019- 2028
Figure 10. Europe Virology Market Revenue Share, by Type (2021 and 2028)
Figure 11. Europe Diagnostic Test: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Europe DNA Virus Testing: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Europe RNA Virus Testing: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Europe Others: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Europe Viral Infection Controlling Techniques: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Europe Active Prophylaxis: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Europe Passive Prophylaxis: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Europe Antiviral Therapeutics : Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. Europe Virucidal Agents: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Europe Antiviral Agents: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Europe Immunomodulators: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Europe Interferons: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. Europe Virology Market, by Application 2021 & 2028 (%)
Figure 24. Europe Skin and Soft Tissue Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Europe Respiratory Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Europe GI Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Europe Sexually Transmitted Diseases: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. Europe Urinary Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Europe Others: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. Europe Virology Market Revenue Share, by End User (2021 and 2028)
Figure 31. Europe Hospitals: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. Europe Diagnostic Laboratories: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. Europe Pharmaceutical and Biotechnological Companies: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. Europe Research and Academic Institutes: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. Europe: Virology Market Revenue Overview, by Country, 2021 (US$ MN)
Figure 36. Europe Virology Market Revenue and Forecasts to 2028, By Country (%)
Figure 37. UK Virology Market Revenue and Forecasts to 2028 (US$ million)
Figure 38. Germany Virology Products Market Revenue and Forecasts to 2028 (US$ million)
Figure 39. France Virology Market Revenue and Forecasts to 2028 (US$ million)
Figure 40. Italy Virology Market Revenue and Forecasts to 2028 (US$ million)
Figure 41. Spain Virology Market Revenue and Forecasts to 2028 (US$ million)
Figure 42. Rest of Europe Virology Market Revenue and Forecasts to 2028 (US$ million)
Figure 43. Impact of COVID-19 Pandemic on Virology Market in European Countries
- Abbott
- AbbVie Inc.
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- GlaxoSmithKline Plc
- Illumina, Inc.
- Johnson and Johnson Services, Inc.
- QIAGEN
- Siemens AG
- Thermo Fisher Scientific Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe Virology market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Europe Virology market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Virology market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution